DSIP vs Pinealon.

DSIP (Delta Sleep-Inducing Peptide) is a small endogenous nonapeptide with the amino acid sequence Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu (WAGGDASGE), molecular weight roughly 850 Da. It was first isolated in 1974 by Schoenenberger, Monnier and colleagues in Switzerland from the cerebral venous blood of rabbits placed in an electrically induced state of slow-wave (delta) sleep, and named for that apparent sleep-promoting property. DSIP-like immunoreactive material has since been detected in various mammalian tissues and human fluids (including breast milk), but it remains a biochemical "riddle": no gene, precursor protein, or specific receptor for it has been definitively identified.

Pinealon is a synthetic ultrashort tripeptide with the sequence glutamic acid–aspartic acid–arginine (Glu-Asp-Arg, abbreviated EDR). It belongs to the class of "peptide bioregulators" developed in Russia by Vladimir Khavinson and colleagues at the St. Petersburg Institute of Bioregulation and Gerontology, who designed short peptides intended to mirror regulatory sequences associated with the pineal gland. It is a research chemical, not an approved drug.

DSIP has no single confirmed receptor or signaling pathway; its mechanism remains genuinely unresolved despite decades of study. Reported preclinical interactions are diffuse and concentration-dependent, including modulation of NMDA-receptor activity, effects on glucocorticoid/stress-axis regulation, and engagement of MAPK signaling cascades, along with proposed influences on GABAergic, opioid/enkephalin, and somatostatin systems. It does not behave like a classical hypnotic acting at a defined target; instead it has been framed as a neuromodulator or "homeostatic" regulator with dose- and timing-dependent, sometimes bidirectional, effects on arousal. Its very short circulating half-life (on the order of minutes) further complicates any straightforward receptor-occupancy mechanism.

The proposed mechanism, advanced primarily by the Khavinson group, is that short peptides like EDR penetrate cell and nuclear membranes and interact directly with DNA and chromatin to act as epigenetic modulators of gene expression and protein synthesis. In cell and biophysical studies the EDR peptide has been reported to bind deoxyribooligonucleotides/DNA and to enter the nucleus of HeLa cells, and proposed downstream effects include reduced reactive oxygen species, modulation of MAPK/ERK signaling, lowered pro-apoptotic markers (caspase-3, p53), increased antioxidant enzymes (SOD2, GPX1), and stimulation of serotonin-related (tryptophan hydroxylase) expression in cortical neurons. These are mechanistic hypotheses derived largely from in vitro and computational/biophysical work rather than from established receptor pharmacology.

Human data exist but are old, small, and mixed. Small studies from the early 1980s (e.g., Schneider-Helmert and colleagues, Experientia 1981; Int J Clin Pharmacol Ther Toxicol 1981) reported acute and delayed improvements in sleep efficiency, latency and continuity in insomniac and normal subjects after intravenous DSIP, with good tolerability. However, a later double-blind matched-pairs study in 16 chronic insomniacs (Neuropsychobiology, 1992) found higher sleep efficiency and shorter latency yet concluded short-term DSIP is "not likely to be of major therapeutic benefit." A 1984 clinical trial (European Neurology) and a pilot study in chronic pain also reported effects, and a 2009 anaesthesia study (European Journal of Anaesthesiology) found DSIP altered bispectral index/EEG as an isoflurane adjunct. A 2006 Journal of Neurochemistry review explicitly calls DSIP "a still unresolved riddle," underscoring that no modern, adequately powered, registration-quality trial has confirmed a clinical sleep benefit.

There are no completed human efficacy trials of pinealon; the evidence base is preclinical (in vitro cell culture, biophysical, and rodent) and clusters heavily around a single research lineage. Reported findings include increased neuronal cell viability and suppression of free radicals in culture (Khavinson, Rejuvenation Research 2011), nuclear penetration and DNA binding of fluorescently labeled short peptides (Fedoreyeva, Biochemistry Moscow 2011), stimulation of serotonin expression in brain cortex cells (Khavinson, Bull Exp Biol Med 2014), and antioxidant/neuroprotective effects in aged-rat hypoxia and carotid-occlusion models (Mendzheritsky, Adv Gerontol 2011, 2014). A 2020 Molecules review by the developers frames EDR as a candidate neuroprotective agent for early Alzheimer's disease, but it is a hypothesis-generating review of the group's own animal and in vitro data, not clinical proof. Independent, non-affiliated replication is essentially absent, so reported effects should be treated as preliminary.

In the small historical human studies DSIP was generally described as well tolerated with few reported acute side effects, including reports of no daytime sedation hangover. However, these trials were tiny, short-term, and decades old, so the safety database is thin and there is essentially no modern controlled long-term safety, immunogenicity, or chronic-exposure data. Material sold for "research" is unregulated, of unverified purity and identity, and not produced to pharmaceutical standards, which introduces contamination and mislabeling risks independent of the peptide itself. Long-term effects, drug interactions, and effects in any specific population remain unknown.

Documented safety data in humans are effectively nonexistent; there are no published controlled human safety or pharmacokinetic trials, and no established toxicology dossier in the peer-reviewed literature. Materials sold as "pinealon" are research chemicals not manufactured to pharmaceutical GMP standards, so identity, purity, sterility, and endotoxin content are unverified and vary by vendor. Long-term effects, immunogenicity, and any consequences of the proposed DNA-interacting mechanism are unstudied in humans. Because the compound is unapproved and unregulated for human use, its risk profile is genuinely unknown rather than established as safe.

DSIP is not approved by the FDA (or, to public knowledge, any major regulator) as a drug for sleep or any other indication; it has only ever been an investigational/experimental compound and is currently sold as a research-use-only chemical. It is not a WADA-prohibited substance by name, but it is not a legitimate, quality-controlled medicine.

Pinealon is not approved by the FDA or, to public knowledge, any major regulatory authority; it has no ATC code and no standard pharmaceutical identifiers (DrugBank/KEGG/UNII), and is sold only as a research-use-only chemical. It is not a recognized therapeutic and is not WADA-listed as a named substance, though related growth/peptide categories may fall under broader anti-doping provisions.